SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-179313
Filing Date
2024-07-16
Accepted
2024-07-16 06:16:02
Documents
16
Period of Report
2024-07-15
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d871272d8k.htm   iXBRL 8-K 33442
2 EX-99.1 d871272dex991.htm EX-99.1 401309
3 EX-99.2 d871272dex992.htm EX-99.2 953599
7 GRAPHIC g871272sp188.jpg GRAPHIC 18070
  Complete submission text file 0001193125-24-179313.txt   1769565

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA eigrq-20240715.xsd EX-101.SCH 2514
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE eigrq-20240715_lab.xml EX-101.LAB 17956
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eigrq-20240715_pre.xml EX-101.PRE 11239
19 EXTRACTED XBRL INSTANCE DOCUMENT d871272d8k_htm.xml XML 3779
Mailing Address 2155 PARK BOULEVARD PALO ALTO CA 94306
Business Address 2155 PARK BOULEVARD PALO ALTO CA 94306 650-279-9845
Eiger BioPharmaceuticals, Inc. (Filer) CIK: 0001305253 (see all company filings)

IRS No.: 361004130 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36183 | Film No.: 241118550
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)